Celcuity Inc. (CELC) stock
CELCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$64.17−0.15 (-0.23%)
Close on Nov 12, 2026Market cap $3.14BP/E –Yield –
Celcuity r&d expenses
Research and development expenses are spending on new products and technology.
Celcuity's R&D Expenses for the twelve months ending Sep 30, 2026 was $150.06M, up 15.4% year over year. For fiscal 2025 it was $145.00M, up 39.1% from the year before. The highest annual figure on record is $145.00M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.00M | +39.1% |
| FY2024 | Dec 31, 2024 | $104.20M | +72.0% |
| FY2023 | Dec 31, 2023 | $60.59M | +71.7% |
| FY2022 | Dec 31, 2022 | $35.29M | +37.0% |
| FY2021 | Dec 31, 2021 | $25.76M | +235.2% |
| FY2020 | Dec 31, 2020 | $7.68M | +22.6% |
| FY2019 | Dec 31, 2019 | $6.27M | -0.9% |
| FY2018 | Dec 31, 2018 | $6.33M | +27.0% |
| FY2017 | Dec 31, 2017 | $4.98M | +62.5% |
| FY2016 | Dec 31, 2016 | $3.06M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $37.52M | +23.3% |
| Q2 FY2026 | Jun 30, 2026 | $31.08M | -14.7% |
| Q1 FY2026 | Mar 31, 2026 | $33.06M | +11.1% |
| Q4 FY2025 | Dec 31, 2025 | $48.40M | +44.6% |
| Q3 FY2025 | Sep 30, 2025 | $30.43M | +10.3% |
| Q2 FY2025 | Jun 30, 2025 | $36.42M | +61.9% |
| Q1 FY2025 | Mar 31, 2025 | $29.76M | +44.1% |
| Q4 FY2024 | Dec 31, 2024 | $33.47M | +85.1% |
| Q3 FY2024 | Sep 30, 2024 | $27.59M | +57.8% |
| Q2 FY2024 | Jun 30, 2024 | $22.50M | +63.7% |
| Q1 FY2024 | Mar 31, 2024 | $20.65M | +83.1% |
| Q4 FY2023 | Dec 31, 2023 | $18.08M | +70.5% |
| Q3 FY2023 | Sep 30, 2023 | $17.49M | +81.8% |
| Q2 FY2023 | Jun 30, 2023 | $13.75M | +64.3% |
| Q1 FY2023 | Mar 31, 2023 | $11.28M | +68.4% |
| Q4 FY2022 | Dec 31, 2022 | $10.60M | +93.1% |
| Q3 FY2022 | Sep 30, 2022 | $9.62M | +94.0% |
| Q2 FY2022 | Jun 30, 2022 | $8.37M | -36.0% |
| Q1 FY2022 | Mar 31, 2022 | $6.70M | +199.4% |
| Q4 FY2021 | Dec 31, 2021 | $5.49M | +160.6% |
| Q3 FY2021 | Sep 30, 2021 | $4.96M | +152.8% |
| Q2 FY2021 | Jun 30, 2021 | $13.07M | +640.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.24M | +21.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.11M | +40.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.96M | +14.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.77M | +20.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.85M | +16.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.50M | -8.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.71M | +7.0% |
| Q2 FY2019 | Jun 30, 2019 | $1.47M | -5.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.59M | +2.9% |
| Q4 FY2018 | Dec 31, 2018 | $1.63M | +16.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.60M | +17.2% |
| Q2 FY2018 | Jun 30, 2018 | $1.55M | +18.6% |
| Q1 FY2018 | Mar 31, 2018 | $1.55M | +70.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.40M | +67.1% |
| Q3 FY2017 | Sep 30, 2017 | $1.36M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $908.77K | – |
| Q4 FY2016 | Dec 31, 2016 | $839.90K | – |
See a number that looks wrong?